Fanconi Anemia Complementation Group F Protein
"Fanconi Anemia Complementation Group F Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Fanconi anemia complementation group protein. It is an essential component of a nuclear core complex that protects the GENOME against CHROMOSOMAL INSTABILITY. It interacts directly with FANCG PROTEIN and helps stabilize a complex with FANCA PROTEIN and FANCC PROTEIN.
Below are MeSH descriptors whose meaning is more general than "Fanconi Anemia Complementation Group F Protein".
Below are MeSH descriptors whose meaning is more specific than "Fanconi Anemia Complementation Group F Protein".
This graph shows the total number of publications written about "Fanconi Anemia Complementation Group F Protein" by people in Harvard Catalyst Profiles by year, and whether "Fanconi Anemia Complementation Group F Protein" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Fanconi Anemia Complementation Group F Protein" by people in Profiles.
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009 Jul 14; 8:48.
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl). 2007 May; 85(5):497-509.
Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem. 2007 Jan 19; 282(3):2047-55.
Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol. 2003 Nov; 123(3):469-71.
The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle. 2003 Jul-Aug; 2(4):290-2.
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003 May; 9(5):568-74.
Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. Hum Mol Genet. 2002 Dec 01; 11(25):3125-34.
Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Exp Hematol. 2001 Dec; 29(12):1448-55.